There is research on this stock available only to PRO subscribers.
There are no Transcripts on AHRO.
PR Newswire (Jul 30, 2014)
GlobeNewswire (Jul 15, 2014)
AtheroNova Announces Russian Ministry of Healthcare Approval for Initiation of Phase 1b Trial Investigating AHRO-001GlobeNewswire (May 28, 2014)
We currently have no Breaking News on this stock.
AHRO vs. ETF Alternatives
AtheroNova Inc. is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. Atherosclerotic plaque, which progressively narrows and blocks arteries, is the main underlying pathology of... More
Other News & PR